NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis $15.48 +0.64 (+4.31%) (As of 05:15 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends About Arcturus Therapeutics Stock (NASDAQ:ARCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arcturus Therapeutics alerts:Sign Up Key Stats Today's Range$14.61▼$15.8050-Day Range$14.82▼$21.4652-Week Range$14.30▼$45.00Volume812,427 shsAverage Volume467,977 shsMarket Capitalization$419.31 millionP/E RatioN/ADividend YieldN/APrice Target$66.75Consensus RatingBuy Company OverviewArcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Read More… Arcturus Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreARCT MarketRank™: Arcturus Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 536th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingArcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Arcturus Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($2.31) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -6.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -6.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.78% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in Arcturus Therapeutics has recently decreased by 2.46%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth.Read more about Arcturus Therapeutics' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.78% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in Arcturus Therapeutics has recently decreased by 2.46%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment0.36 News SentimentArcturus Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.Search Interest10 people have searched for ARCT on MarketBeat in the last 30 days. MarketBeat FollowsOnly 3 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $249,120.00 in company stock.Percentage Held by Insiders15.30% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcturus Therapeutics' insider trading history. Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARCT Stock News HeadlinesWe're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn RateDecember 20 at 10:25 AM | finance.yahoo.comArcturus Therapeutics' (ARCT) Buy Rating Reiterated at HC WainwrightDecember 20 at 4:15 AM | americanbankingnews.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.December 20, 2024 | Crypto Swap Profits (Ad)Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Madrigal Pharmaceuticals (MDGL)December 18 at 5:44 AM | markets.businessinsider.comArcturus Therapeutics: Promising COVID-19 Vaccine Advancements and Strategic Collaborations Justify Buy RatingDecember 17 at 7:42 PM | markets.businessinsider.comArcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 16, 2024 | finance.yahoo.comWhy Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short SellersDecember 11, 2024 | finance.yahoo.comPositive Outlook for Arcturus Therapeutics Driven by Innovative Vaccine KostaiveDecember 6, 2024 | markets.businessinsider.comSee More Headlines ARCT Stock Analysis - Frequently Asked Questions How have ARCT shares performed this year? Arcturus Therapeutics' stock was trading at $31.53 at the beginning of the year. Since then, ARCT stock has decreased by 50.9% and is now trading at $15.48. View the best growth stocks for 2024 here. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) posted its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.44. The biotechnology company had revenue of $41.67 million for the quarter, compared to analysts' expectations of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative trailing twelve-month return on equity of 22.39%. Who are Arcturus Therapeutics' major shareholders? Arcturus Therapeutics' top institutional shareholders include Sumitomo Mitsui Trust Group Inc. (8.45%), ARK Investment Management LLC (7.80%), State Street Corp (5.44%) and Geode Capital Management LLC (2.04%). Insiders that own company stock include Pad Chivukula, Magda Marquet and Keith C Kummerfeld. View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD). Company Calendar Last Earnings11/07/2024Today12/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARCT CUSIPN/A CIK1410997 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Target$66.75 High Stock Price Target$86.00 Low Stock Price Target$48.00 Potential Upside/Downside+329.8%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,730,000.00 Net Margins-36.39% Pretax Margin-38.15% Return on Equity-22.39% Return on Assets-14.81% Debt Debt-to-Equity RatioN/A Current Ratio4.76 Quick Ratio4.76 Sales & Book Value Annual Sales$142.47 million Price / Sales2.95 Cash FlowN/A Price / Cash FlowN/A Book Value$10.42 per share Price / Book1.49Miscellaneous Outstanding Shares27,087,000Free Float22,943,000Market Cap$420.66 million OptionableOptionable Beta2.62 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:ARCT) was last updated on 12/20/2024 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBitcoin is going to $100,000 … before Inauguration DayMark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMusk threatens Liberal’s fake “energy crisis”Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people a...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.